A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars

RXi Pharmaceuticals

Status and phase: Unknown; Phase 2

Conditions: Hypertrophic Scar

Treatments: Drug: RXI-109

Study type: Interventional

Funder types: Industry

Identifiers

NCT02246465

RXI-109-1402

Details and patient eligibility

About

The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic scar.

Enrollment: 40 estimated patients

Sex: All

Ages: 21 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adults, 21-55 years of age
• General good health
• Previous surgery or injury resulting in a hypertrophic scar

Exclusion criteria

• Scars on the face or front of neck may not be included in the trial
• Use of tobacco or nicotine-containing products
• Pregnant or lactating

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

RXI-109

Experimental group

Description:

RXI-109 dosed at the site of the revised hypertrophic scar

Treatment:

Drug: RXI-109